Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04284202 | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | unknown | Phase 2 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 25, 2020 |
| clinicaltrials |
| NCT01405079 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation(ADJUVANT) | unknown | Phase 3 | 222 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT04266483 | Cancer Genome Atlas of China:Lung Cancer | unknown | — | 2,500 | Xuanwu Hospital, BeijingOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02725918 | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure | unknown | Phase 2 | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT04263688 | Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion | unknown | — | 300 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Feb 12, 2020 | clinicaltrials |
| NCT03605602 | A Real World Study Based on NGS (TRUMPRWS)(TRUMPRWS) | unknown | — | 2,700 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03301961 | Multiplex Analysis of Circulating Tumor DNA | unknown | — | 400 | Peking University People's HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03557411 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04252365 | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | unknown | Phase 2 | 20 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04255836 | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT01795521 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC(LungTech) | unknown | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 31, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239833 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | unknown | Phase 3 | 240 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jan 27, 2020 | clinicaltrials |
| NCT03827577 | OMEGA, Local Ablative Therapy in Oligometastatic NSCLC(OMEGA) | unknown | Phase 3 | 195 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04229121 | Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 18, 2020 | clinicaltrials |
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | unknown | Phase 2 | 84 | Hunan Cancer HospitalOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03741647 | Sleep Apnea and Lung Cancer | unknown | — | 50 | Zagazig UniversityOTHER_GOV | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04213170 | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04137718 | Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation | unknown | — | 50,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04066335 | Study to Evaluate the Safety of Nanoxel M Inj. | unknown | — | 1,498 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04193007 | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC(BRATR) | unknown | Phase 2 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04181372 | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | unknown | Phase 2 | 50 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04180501 | SRS Sequential Sindilimab in Brain Metastasis of NSLSC | unknown | Phase 2 | 25 | Xiaorong DongOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04167774 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC(Compass-001) | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | unknown | Phase 1 | 84 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04164745 | Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | unknown | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04161352 | Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC(R-helper) | unknown | — | 500 | Zhejiang Cancer HospitalOTHER | 0 | Nov 13, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04153526 | LUCID - LUng Cancer CIrculating Tumour Dna Study(LUCID) | unknown | — | 100 | CCTU- Cancer ThemeOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04009317 | Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04056572 | Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | unknown | Phase 2 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04132102 | To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation | unknown | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT03769805 | Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC(CSOAIMTOAN) | unknown | N/A | 83 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04131543 | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC(CRETA) | unknown | Phase 2 | 25 | University of BolognaOTHER | 1 | Oct 18, 2019 | clinicaltrials |
| NCT04124731 | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | unknown | Phase 2 | 98 | Shanghai Chest HospitalOTHER | 0 | Oct 11, 2019 | clinicaltrials |
| NCT04116918 | Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC | unknown | — | 100 | Baodong QinOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT04111913 | A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04108013 | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | unknown | Phase 2 | 38 | Xuanwu Hospital, BeijingOTHER | 0 | Sep 27, 2019 | clinicaltrials |
| NCT04106180 | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT04054531 | Study of KN046 With Chemotherapy in First Line Advanced NSCLC | unknown | Phase 2 | 50 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Feb 25, 2020source: clinicaltrials